486
J. Ortner et al. / Carbohydrate Research 327 (2000) 483–487
The crude culture filtrate used in this study
Methyl 2,3,6-tri-O-acetyl-4-O-[2,3,6-tri-O-
was from the strain Thermoascus aurantiacus
acetyl - 4 - O - (2,3,4,6 - tetra - O - acetyl - i -
galactopyranosyl)-i- -glucopyranosyl]-i-
D
-
-
Miehe, and was prepared according to Ref.
D
D
[
8].
glucopyranoside (peracetate of 8).—b-Lactosyl
Procedure A.—To a soln of the donor (0.20
fluoride (7, 200 mg, 0.58 mmol) and methyl
M) in acetate buffer (pH 5.0, 50 mM) contain-
ing 20 vol% MeOH, the lyophilised culture
filtrate (0.5–1 mg per mg donor) was added
and the mixture was shaken at room tempera-
ture (rt) until all the donor was consumed
b- -glucopyranoside (2, 338 mg, 1.74 mmol)
D
were treated according to procedure B yielding
a mixture of regioisomeric trisaccharides (105
mg, S 19%, colourless oil). By repeated
column chromatography (1:1 cyclohexane–
EtOAc), a clean fraction of the title compound
(
typically overnight). After addition of toluene
2
0
and evaporation of the solvent under dimin-
ished pressure, the products were isolated by
was isolated and characterised; [h] −11° (c
D
0
.15, CH Cl ); R 0.33 (1:2 cyclohexane–
2
2
f
column chromatography (5:1 CHCl –MeOH).
13
3
EtOAc); C NMR (50.29 MHz, CDCl ): l
3
Procedure B.—To a soln of the donor (0.50
1
(
7
7
70.4–169.2 (OAc), 101.5, 101.2 and 100.6
M) and acceptor (1.5 M) in acetate buffer (pH
C-1, 1%, 1¦), 76.6 and 76.1 (C-4, 4%), 73.1, 72.8,
5
(
.0, 50 mM), the lyophilised culture filtrate
2.8, 72.6, 72.0 and 71.7 (C-2, 3, 5, 2%, 3%, 5%),
1.1 and 70.9 (C-3¦, 5¦), 66.7 (C-4¦), 62.4, 61.9
1–2 mg per mg donor) was added and the
reaction mixture was shaken at rt until all the
donor was consumed. After addition of
toluene and evaporation of the solvent under
diminished pressure, the crude product mix-
and 60.9 (C-6, 6%, 6¦), 57.1 (OMe), 21.0–20.6
1
(
(
OAc); H NMR (199.98 MHz, CDCl ): l 5.34
3
bd, 1 H, J3¦,4¦ 3.3 Hz, H-4¦), 5.16 and 5.13 (t
each, 1 H each, J =J =J =J 9.2 Hz,
2
,3
3,4
2%,3%
3%,4%
ture was acetylated in Ac O–pyridine. After
2
H-3, 3%), 5.09 (dd, 1 H, J1¦,2¦ 8.1 Hz, J2¦,3¦ 10.3
Hz, H-2¦), 4.93 (dd, 1 H, H-3¦), 4.88 and 4.83
extractive work-up, the peracetates were iso-
lated by column chromatography (2:1
cyclohexane–EtOAc).
(
4
(
3
3
4
dd each, 1 H each, J =J 7.8 Hz, H-2, 2%),
1
,2
1%,2%
.49 and 4.43 (d each, 1 H each, H-1, 1%), 4.37
Methyl
tetra - O - acetyl - i -
glucopyranoside (peracetate of 6).—p-Nitro-
phenyl b- -glucopyranoside (5, 176 mg, 0.58
mmol) and methyl b- -glucopyranoside (2,
40 mg, 1.75 mmol) were brought to reaction
2,3,4-tri-O-acetyl-6-O-(2,3,4,6-
d, 1 H, H-1¦), 4.0–4.6 (m, 6 H, H-6, 6%, 6¦),
D
- glucopyranosyl) - i -
D-
.85 (bd, 1 H, J
.76 (t each, 1 H each, J =J 9.2 Hz, H-4,
6.6 Hz, H-5¦), 3.78 and
5
¦,6¦
4
,5
4%,5%
D
%), 3.5–3.65 (m, 2 H, H-5, 5%), 3.47 (s, 3 H,
OMe), 2.20–1.95 (m, 30 H, 10 OAc).
D
3
Methyl
tetra - O - acetyl - h -
2,3,4-tri-O-acetyl-6-O-(2,3,4,6-
as described in procedure B yielding the title
compound (95 mg, 25%) as a colourless oil.
D
- mannopyranosyl) - h - -
D
2
0
mannopyranoside (peracetate of 11).—Appli-
[
h] −20° (c 1.35, CHCl ); R 0.42 (1:1 cyclo-
D
3
f
13
cation of procedure B to a mixture of a- or
hexane–EtOAc);
CDCl ): l 170.7–169.3 (OAc), 101.5 and 100.8
C NMR (50.29 MHz,
b- -mannopyranosyl fluoride (12 or 3, 150
D
3
mg, 0.823 mmol) and methyl a- -mannopyra-
D
(
7
C-1, 1%), 73.3 (C-5), 72.8 and 72.8 (C-3, 3%),
2.0 (C-5%), 71.3 and 71.1 (C-2, 2%), 69.2, 68.3
and 68.3 (C-4, 6, 4%), 61.8 (C-6%), 57.1 (OMe),
noside (10, 480 mg, 2.47 mmol) led to the title
compound as a colourless oil (43 or 59 mg, 8
2
0
1
or 11%, respectively). [h] +72° (c 1.10,
2
0.7–20.6 (OAc); H NMR (300.13 MHz,
D
1
3
CHCl ); R 0.26 (1:1 cyclohexane–EtOAc); C
CDCl ): l 5.13 (t, 2 H, J =J =J2%,3%=J3%,4%
3
f
3
2,3
3,4
NMR (50.29 MHz, CDCl ): l 170.6–169.8
9
.5 Hz, H-3, 3%), 4.92 and 4.85 (dd each, 1 H
3
(
(
OAc), 98.4 (JC-1,H-1 172.2 Hz, C-1), 97.5
JC-1,H-1 172.8 Hz, C-1%), 69.5, 69.4, 69.2, 69.1,
69.0, 68.7, 66.6 and 66.0 (C-2, 3, 4, 5, 2%, 3%, 4%,
each, J =J 8.0 Hz, H-2, 2%), 5.00 and 4.82
1
,2
1%,2%
(
t each, 1 H each, J =J
9.5 Hz, H-4, 4%),
4
,5
4%,5%
4
.54 and 4.33 (d each, 1 H each, H-1, 1%), 4.20
(
dd, 1 H, J5%,6%a 4.8 Hz, J6%a,6%b 12.4 Hz, H-6%a),
.05 (bd, 1 H, H-6%b), 3.81 (bd, 1 H, J6a,6b 10.5
Hz, H-6a), 3.67–3.60 (m, 2 H, H-5, 5%), 3.55
dd, 1 H, J5,6b 7.4 Hz, H-6b), 3.44 (s, 3 H,
OMe), 2.1–1.9 (m, 21 H, 7 OAc).
5%), 66.7 (C-6), 62.4 (C-6%), 55.3 (OMe), 20.9–
1
4
20.7 (OAc); H NMR (199.98 MHz, CDCl ): l
3
5.40–5.15 (m, 6 H, H-2, 3, 4, 2%, 3%, 4%), 4.83
and 4.67 (d each, 1 H each, J =J 1.3 Hz,
(
1,2
1%,2%
H-1, 1%), 4.22 (dd, 1 H, J5%,6%a 5.4 Hz, J6%a,6%b